An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Tauvid

Chemical Nameflortaucipir F18
Dosage FormInjection (intravenous; 300 MBq/mL to 1,900 MBq/mL)
Drug ClassRadioactive agents
SystemNervous
CompanyAvid Radiopharmaceuticals
Approval Year2020

Indication

  • Indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD).
Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tauvid (flortaucipir F18) Prescribing Information.2020Avid Radiopharmaceuticals, a wholly-owned subsidiary of Eli Lilly and Company, Philadelphia, PA
Document TitleYearSource
Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study.2020EJNMMI Research
A reader study to assess accuracy and reliability of flortaucipir F 18 PET scan interpretation.2020Avid Radiopharmaceuticals